FI20000480A0 - Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina - Google Patents
Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteinaInfo
- Publication number
- FI20000480A0 FI20000480A0 FI20000480A FI20000480A FI20000480A0 FI 20000480 A0 FI20000480 A0 FI 20000480A0 FI 20000480 A FI20000480 A FI 20000480A FI 20000480 A FI20000480 A FI 20000480A FI 20000480 A0 FI20000480 A0 FI 20000480A0
- Authority
- FI
- Finland
- Prior art keywords
- quinoline
- antagonists
- alpha
- naphthalene derivatives
- naphthalene
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 title 1
- 150000002790 naphthalenes Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20000480A FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
HU0204458A HUP0204458A3 (en) | 2000-03-01 | 2001-02-28 | Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them |
CNA018059236A CN1468224A (zh) | 2000-03-01 | 2001-02-28 | 用作α-2拮抗剂的喹啉衍生物 |
IL15109301A IL151093A0 (en) | 2000-03-01 | 2001-02-28 | Derivatives of quinoline as alpha-2 antagonists |
MXPA02008402A MXPA02008402A (es) | 2000-03-01 | 2001-02-28 | Derivados de quinolina como antagonistas alfa-2. |
RU2002125944/04A RU2002125944A (ru) | 2000-03-01 | 2001-02-28 | Производные хинолина в качестве альфа-2-антагонистов |
EEP200200490A EE200200490A (et) | 2000-03-01 | 2001-02-28 | Kinoliini derivaadid alfa-2 antagonistidena |
EP01913918A EP1263733A2 (de) | 2000-03-01 | 2001-02-28 | Quinolin-derivate als alpha-2 antagonisten |
BR0108816-5A BR0108816A (pt) | 2000-03-01 | 2001-02-28 | Derivados de quinolina como antagonistas alfa-2 |
KR1020027011453A KR20020089372A (ko) | 2000-03-01 | 2001-02-28 | 알파-2 길항제로서의 퀴놀린 유도체 |
CA002400657A CA2400657A1 (en) | 2000-03-01 | 2001-02-28 | Derivatives of quinoline as alpha-2 antagonists |
SK1233-2002A SK12332002A3 (sk) | 2000-03-01 | 2001-02-28 | Deriváty chinolínu ako alfa 2 antagonisty |
AU2001239331A AU2001239331A1 (en) | 2000-03-01 | 2001-02-28 | Derivatives of quinoline as alpha-2 antagonists |
PL01357874A PL357874A1 (en) | 2000-03-01 | 2001-02-28 | Derivatives of quinoline as alpha-2 antagonists |
PCT/FI2001/000203 WO2001064645A2 (en) | 2000-03-01 | 2001-02-28 | Derivatives of quinoline as alpha-2 antagonists |
CZ20022880A CZ20022880A3 (cs) | 2000-03-01 | 2001-02-28 | Deriváty chinolinu jako alfa 2 antagonisté |
JP2001563488A JP2003525274A (ja) | 2000-03-01 | 2001-02-28 | α2−アンタゴニストとしてのキノリン誘導体 |
ARP010100993A AR034249A1 (es) | 2000-03-01 | 2001-03-01 | Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones |
PE2001000208A PE20011084A1 (es) | 2000-03-01 | 2001-03-01 | Derivados de quinolina como antagonistas alfa-2 |
ZA200206956A ZA200206956B (en) | 2000-03-01 | 2002-08-29 | Derivatives of quinoline as alpha-2 antagonists. |
NO20024159A NO20024159L (no) | 2000-03-01 | 2002-08-30 | Derivater av kinolin som alfa-2 antagonister |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20000480A FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
Publications (1)
Publication Number | Publication Date |
---|---|
FI20000480A0 true FI20000480A0 (fi) | 2000-03-01 |
Family
ID=8557801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20000480A FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1263733A2 (de) |
JP (1) | JP2003525274A (de) |
KR (1) | KR20020089372A (de) |
CN (1) | CN1468224A (de) |
AR (1) | AR034249A1 (de) |
AU (1) | AU2001239331A1 (de) |
BR (1) | BR0108816A (de) |
CA (1) | CA2400657A1 (de) |
CZ (1) | CZ20022880A3 (de) |
EE (1) | EE200200490A (de) |
FI (1) | FI20000480A0 (de) |
HU (1) | HUP0204458A3 (de) |
IL (1) | IL151093A0 (de) |
MX (1) | MXPA02008402A (de) |
NO (1) | NO20024159L (de) |
PE (1) | PE20011084A1 (de) |
PL (1) | PL357874A1 (de) |
RU (1) | RU2002125944A (de) |
SK (1) | SK12332002A3 (de) |
WO (1) | WO2001064645A2 (de) |
ZA (1) | ZA200206956B (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1474401A2 (de) * | 2002-02-05 | 2004-11-10 | Novo Nordisk A/S | Neue aryl- und heteroarylpiperazine |
ATE521593T1 (de) * | 2002-04-03 | 2011-09-15 | Orion Corp | Verwendung eines alfa2-adrenorezeptorantagonisten bei mit dem zns zusammenhängenden erkrankungen |
MXPA04009601A (es) | 2002-04-03 | 2004-12-13 | Orion Corp | Compuestos policiclicos como potentes antagonistas del adreno-receptor alfa-2. |
US7009053B2 (en) * | 2002-04-30 | 2006-03-07 | Yungjin Pharmaceuticals Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
WO2004067513A1 (en) * | 2003-01-27 | 2004-08-12 | Oy Juvantia Pharma Ltd | Antagonists for alpha-2 adrenoceptors |
RU2499795C2 (ru) | 2005-07-04 | 2013-11-27 | Хай Пойнт Фармасьютикалс, ЛЛС | Антагонисты гистаминовых н3-рецепторов |
EP1948629A1 (de) | 2005-10-31 | 2008-07-30 | Janssen Pharmaceutica N.V. | Substituierte piperazine und piperidine als modulatoren des neuropeptid-y2-rezeptors |
CA2636929A1 (en) * | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
CA2649707A1 (en) * | 2006-05-22 | 2007-11-29 | Janssen Pharmaceutica N.V. | Substituted pyrazinone derivatives for use as a medicine |
JP2009537596A (ja) | 2006-05-23 | 2009-10-29 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用 |
WO2007137968A1 (en) | 2006-05-29 | 2007-12-06 | High Point Pharmaceuticals, Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
EP2014656A3 (de) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Neue heterocyclische H3-Antagonisten |
TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物 |
TW201026691A (en) | 2008-10-07 | 2010-07-16 | Schering Corp | Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators |
TW201024282A (en) | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
EP2509953B1 (de) | 2009-12-11 | 2016-03-30 | Genecode AS | Verfahren für das überleben von nervenzellen mit ligandenmimetika der gdnf-familie oder aktivatoren des ret-signalweges |
CN103524413B (zh) * | 2012-07-04 | 2016-04-20 | 江苏先声药物研究有限公司 | 氢化吖啶衍生物及其应用 |
JOP20200052A1 (ar) * | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
EP3125891A4 (de) * | 2014-03-31 | 2017-08-09 | Mirx Pharmaceuticals, LLC | Neuartige hdmx-inhibitoren und deren verwendung zur behandlung von krebs |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
CN107337641B (zh) * | 2017-07-01 | 2020-04-28 | 广东医科大学 | 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用 |
AU2022341967A1 (en) * | 2021-09-07 | 2024-05-16 | Gismo Therapeutics, Inc. | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
-
2000
- 2000-03-01 FI FI20000480A patent/FI20000480A0/fi unknown
-
2001
- 2001-02-28 CN CNA018059236A patent/CN1468224A/zh active Pending
- 2001-02-28 CA CA002400657A patent/CA2400657A1/en not_active Abandoned
- 2001-02-28 SK SK1233-2002A patent/SK12332002A3/sk unknown
- 2001-02-28 IL IL15109301A patent/IL151093A0/xx unknown
- 2001-02-28 HU HU0204458A patent/HUP0204458A3/hu unknown
- 2001-02-28 WO PCT/FI2001/000203 patent/WO2001064645A2/en not_active Application Discontinuation
- 2001-02-28 CZ CZ20022880A patent/CZ20022880A3/cs unknown
- 2001-02-28 KR KR1020027011453A patent/KR20020089372A/ko not_active Application Discontinuation
- 2001-02-28 BR BR0108816-5A patent/BR0108816A/pt not_active Application Discontinuation
- 2001-02-28 AU AU2001239331A patent/AU2001239331A1/en not_active Abandoned
- 2001-02-28 EP EP01913918A patent/EP1263733A2/de not_active Withdrawn
- 2001-02-28 MX MXPA02008402A patent/MXPA02008402A/es unknown
- 2001-02-28 RU RU2002125944/04A patent/RU2002125944A/ru not_active Application Discontinuation
- 2001-02-28 PL PL01357874A patent/PL357874A1/xx not_active Application Discontinuation
- 2001-02-28 EE EEP200200490A patent/EE200200490A/xx unknown
- 2001-02-28 JP JP2001563488A patent/JP2003525274A/ja active Pending
- 2001-03-01 PE PE2001000208A patent/PE20011084A1/es not_active Application Discontinuation
- 2001-03-01 AR ARP010100993A patent/AR034249A1/es unknown
-
2002
- 2002-08-29 ZA ZA200206956A patent/ZA200206956B/en unknown
- 2002-08-30 NO NO20024159A patent/NO20024159L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20011084A1 (es) | 2001-10-25 |
CZ20022880A3 (cs) | 2003-06-18 |
WO2001064645A2 (en) | 2001-09-07 |
RU2002125944A (ru) | 2004-02-27 |
MXPA02008402A (es) | 2003-10-14 |
AR034249A1 (es) | 2004-02-18 |
KR20020089372A (ko) | 2002-11-29 |
PL357874A1 (en) | 2004-07-26 |
WO2001064645A3 (en) | 2001-12-27 |
SK12332002A3 (sk) | 2003-07-01 |
NO20024159D0 (no) | 2002-08-30 |
IL151093A0 (en) | 2003-04-10 |
NO20024159L (no) | 2002-08-30 |
HUP0204458A3 (en) | 2004-07-28 |
ZA200206956B (en) | 2003-12-01 |
HUP0204458A2 (hu) | 2003-04-28 |
CN1468224A (zh) | 2004-01-14 |
CA2400657A1 (en) | 2001-09-07 |
JP2003525274A (ja) | 2003-08-26 |
AU2001239331A1 (en) | 2001-09-12 |
EE200200490A (et) | 2003-12-15 |
EP1263733A2 (de) | 2002-12-11 |
BR0108816A (pt) | 2002-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20000480A0 (fi) | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina | |
ATE503487T1 (de) | Myostatin-antagonisten und verwendungen davon | |
EE200200400A (et) | Kortikotropiini vabastava faktori antagonistid | |
NO20031097L (no) | Kinolinderivater | |
ATE431145T1 (de) | Missbrauchssichere orale opioid-agonist zubereitungen | |
CY2012026I1 (el) | Παραγωγα κουιναζολινης ως αναστολεις vegf | |
EE200300071A (et) | Kinasoliini derivaadid | |
IS6656A (is) | Útskiptar kínasólínafleiður og notkun þeirra sem hemla | |
DK1341791T3 (da) | Thioethersubstituerede imidazoquinoliner | |
DE60031513D1 (de) | Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten | |
DE60026169D1 (de) | Selektive neurokinin-antagonisten | |
DE60132108D1 (de) | Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion | |
DE60139571D1 (de) | Muscarin-antagonisten | |
DK1404357T3 (da) | Gonadotropin-frigivende hormonantagonist i gel-dannende koncentrationer | |
DE50105934D1 (de) | Einzugs- und Pflückeinrichtung | |
DK1163264T3 (da) | Nye LHRH-antagonister med forbedrede oplöselighedsegenskaber | |
EE200200135A (et) | D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid | |
EE200200204A (et) | Asendatud bensimidasooli preparaat | |
DE60138858D1 (de) | Kraftstoffschlauch- Anschlussstruktur und Kraftstoffschlauch | |
NO20031332L (no) | Arylalkan-sulfonamider med endothelin-antagonistaktivitet | |
DE60044426D1 (de) | Weiterleitungsvorrichtung und -Verfahren | |
DE60125981D1 (de) | Amlodipin in form der freien base | |
EE200200653A (et) | alfa-2,4-disulfofenüül-N-tert-butüülnitrooni uuedpreparaadid | |
NO20015237D0 (no) | Integrinreseptor-antagonister | |
DK1392670T3 (da) | Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater |